Cancer cells frequently exhibit resistance to various molecular and nanoscale drugs, which
inevitably affects the drugs' therapeutic outcomes. Overexpression of glutathione (GSH) has …

Cancer is ranked as the second leading cause of death globally. Traditional cancer
therapies including chemotherapy are flawed, with off-target and on-target toxicities on the …

The high glutathione (GSH) content in tumor cells strongly affects the efficiency of
chemodynamic therapy (CDT). Despite devoted efforts, it still remains a formidable …

The intrinsic limits of conventional cancer therapies prompted the development and
application of various nanotechnologies for more effective and safer cancer treatment …

With the improvement of nanotechnology and nanomaterials, redox-responsive delivery
systems have been studied extensively in some critical areas, especially in the field of …

Theranostics provides opportunities for precision cancer therapy. However, theranostic
probes that simultaneously turn on their diagnostic signal and pharmacological action only …

Loss of function in tumor suppressor genes is commonly associated with the
onset/progression of cancer and treatment resistance. The p53 tumor suppressor gene, a …

Minimalist multifunctional platforms for delivering diagnostic and therapeutic agents
effectively and safely into tumor sites are highly desired in nanomedicine. Herein, we …

A versatile breast cancer‐targeting nanocomposite therapeutic combining docetaxel (DXL),
polyvinyl alcohol (PVA) network for controlled release, and silica‐protected magnetic iron …

Bioresponsive polymers have been widely used in drug delivery because of their
degradability. For example, poly (disulfide) s with repeating disulfide bonds in the main …